Repro-Med Systems, Inc. ( (KRMD) ) has released its Q2 earnings. Here is a breakdown of the information Repro-Med Systems, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
KORU Medical Systems, Inc., a prominent player in the medical technology sector, specializes in developing, manufacturing, and commercializing large volume subcutaneous infusion solutions aimed at enhancing patient quality of life.
In its latest earnings report for the second quarter of 2025, KORU Medical Systems announced record-breaking revenues, marking a significant milestone by surpassing $10 million in quarterly revenue for the first time. The company also raised its full-year revenue guidance, reflecting its strong market performance and strategic growth initiatives.
The financial highlights reveal a 21% increase in net revenues to $10.2 million compared to the previous year, driven by strong domestic and international core business growth. The Pharma Services and Clinical Trials segment also saw a substantial 42% revenue increase. Gross profit rose by 18% to $6.5 million, although gross margin slightly decreased due to previous favorable inventory valuation adjustments and current tariff-related charges.
Strategically, KORU Medical has made significant strides with the appointment of a new Chief Commercial Officer and the expansion of its Freedom Infusion System™ for new drug indications. The company also submitted for FDA clearance for a new biologic drug, underscoring its commitment to innovation and market expansion.
Looking ahead, KORU Medical Systems remains optimistic about its growth trajectory, with management confident in its ability to continue delivering shareholder value through strategic investments and disciplined execution. The company anticipates positive cash flow from operations and maintains a strong cash position to support its growth initiatives.